Oppenheimer Weighs in on Jazz Pharmaceuticals PLC’s Q2 2019 Earnings (NASDAQ:JAZZ)

Share on StockTwits

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) – Stock analysts at Oppenheimer lowered their Q2 2019 earnings estimates for Jazz Pharmaceuticals in a research report issued on Wednesday, July 17th. Oppenheimer analyst E. Rajavelu now forecasts that the specialty pharmaceutical company will post earnings per share of $3.28 for the quarter, down from their previous forecast of $3.37. Oppenheimer has a “Buy” rating and a $176.00 price objective on the stock. Oppenheimer also issued estimates for Jazz Pharmaceuticals’ FY2019 earnings at $13.20 EPS.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings data on Tuesday, May 7th. The specialty pharmaceutical company reported $3.27 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.83 by $0.44. The business had revenue of $508.19 million for the quarter, compared to analysts’ expectations of $466.55 million. Jazz Pharmaceuticals had a net margin of 24.88% and a return on equity of 27.35%. The business’s revenue was up 14.3% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.98 earnings per share.

A number of other equities research analysts have also recently commented on the stock. Wells Fargo & Co reiterated a “hold” rating and set a $68.00 price target (up previously from $65.00) on shares of Colgate-Palmolive in a report on Monday, June 17th. Royal Bank of Canada set a $184.00 price target on shares of Jazz Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, July 3rd. Cantor Fitzgerald reiterated a “buy” rating and set a $185.00 price target on shares of Jazz Pharmaceuticals in a report on Tuesday, March 26th. BMO Capital Markets set a $208.00 price target on shares of Jazz Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, July 3rd. Finally, Mizuho set a $148.00 price target on shares of Jazz Pharmaceuticals and gave the company a “hold” rating in a report on Wednesday, July 3rd. One research analyst has rated the stock with a sell rating, five have given a hold rating and thirteen have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $179.41.

Shares of JAZZ opened at $136.62 on Friday. The stock has a market capitalization of $7.83 billion, a PE ratio of 11.16, a PEG ratio of 1.16 and a beta of 1.15. The company has a current ratio of 3.15, a quick ratio of 3.01 and a debt-to-equity ratio of 0.63. Jazz Pharmaceuticals has a fifty-two week low of $113.52 and a fifty-two week high of $181.46. The business has a 50-day simple moving average of $134.77.

Hedge funds have recently modified their holdings of the stock. Amundi Pioneer Asset Management Inc. boosted its holdings in Jazz Pharmaceuticals by 65.9% in the fourth quarter. Amundi Pioneer Asset Management Inc. now owns 371,182 shares of the specialty pharmaceutical company’s stock worth $46,011,000 after purchasing an additional 147,419 shares during the last quarter. Millennium Management LLC boosted its holdings in Jazz Pharmaceuticals by 120.6% in the fourth quarter. Millennium Management LLC now owns 252,406 shares of the specialty pharmaceutical company’s stock worth $31,288,000 after purchasing an additional 138,007 shares during the last quarter. State Board of Administration of Florida Retirement System boosted its holdings in Jazz Pharmaceuticals by 4.2% in the first quarter. State Board of Administration of Florida Retirement System now owns 73,439 shares of the specialty pharmaceutical company’s stock worth $10,498,000 after purchasing an additional 2,974 shares during the last quarter. Envestnet Asset Management Inc. boosted its holdings in Jazz Pharmaceuticals by 16.8% in the first quarter. Envestnet Asset Management Inc. now owns 45,261 shares of the specialty pharmaceutical company’s stock worth $6,470,000 after purchasing an additional 6,496 shares during the last quarter. Finally, LSV Asset Management boosted its holdings in Jazz Pharmaceuticals by 31.0% in the first quarter. LSV Asset Management now owns 1,001,650 shares of the specialty pharmaceutical company’s stock worth $143,185,000 after purchasing an additional 237,190 shares during the last quarter. Institutional investors own 89.81% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.

Recommended Story: Equity Income

Earnings History and Estimates for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.